SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage
biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today
announced that it will report fourth quarter and full year 2017 financial and operating results after the U.S. financial markets
close on Thursday, March 8, 2018. Management will host a conference call and live audio webcast to discuss these results and
provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call and Webcast
To access the live conference call, please dial 844-494-0193 (domestic) or 508-637-5584 (international) and refer to the
conference ID 8496928.
The webcast may be accessed live on the Investor Relations section of the Company’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia
website for 90 days following the call.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the
treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical
defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of
therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy – hypertrophic
cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (MYK-461), a
novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical studies and
is currently being studied in the Phase 2 PIONEER-HCM clinical trial. MYK-491, MyoKardia’s second product candidate, is designed to
increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently
evaluating MYK-491 in a Phase 1b study in DCM patients. A cornerstone of the MyoKardia platform is the Sarcomeric Human
Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and
families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for
patients with serious cardiovascular disease through bold and innovative science.
Contacts:
Michelle Corral
Corporate Communications & Investor Relations
MyoKardia, Inc.
650-351-4690
mcorral@myokardia.com
Beth DelGiacco (Investors)
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com
Steven Cooper (Media)
Edelman
415-486-3264
steven.cooper@edelman.com
